GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Rhea-AI Summary

GH Research PLC (Nasdaq: GHRS) has announced a conference call and webcast scheduled for February 3, 2025, at 8:00 a.m. EST. The purpose is to provide updates on data from their Phase 2b trial of GH001 in treatment-resistant depression (TRD). The trial is characterized as randomized, double-blind, and placebo-controlled. The event will be accessible through advance registration and will be available on the company's website under the Events & Presentations section.

News Market Reaction – GHRS

+69.72%

+69.72% Session move

In the trading session that priced this news, GHRS gained 69.72%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).

To access the conference call, please register in advance here. A live webcast of the call will be available under “Events & Presentations” in the Investors section of GH Research PLC’s website at ghres.com.

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).

About GH001

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where 87.5% of patients with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has the potential to change the way TRD is treated today.

Investor Relations
Julie Ryan
GH Research PLC
investors@ghres.com

FAQ

When will GH Research (GHRS) announce its Phase 2b trial results for GH001?

GH Research will announce the Phase 2b trial results for GH001 in treatment-resistant depression on February 3, 2025, at 8:00 a.m. EST via a conference call and webcast.

What type of clinical trial is GHRS conducting for GH001?

GHRS is conducting a randomized, double-blind, placebo-controlled Phase 2b trial of GH001 for treatment-resistant depression (TRD).

How can investors access GHRS's Phase 2b trial update webcast?

Investors can access the webcast by registering in advance and visiting the 'Events & Presentations' section of GH Research's website at ghres.com.

What indication is GH Research (GHRS) targeting with GH001?

GH Research is targeting treatment-resistant depression (TRD) with their drug candidate GH001.